News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oculus Innovative Sciences, Inc. (OCLS) Announces Agreement with Bayer Australia Limited for Development of Microcyn(R) Technology Use in Australian Animal Market



6/19/2008 8:42:04 AM

PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform that is intended to treat infections in chronic and acute wounds, announced today an agreement with Bayer Australia’s Animal Health division for the development of the Microcyn® Technology for use in the Australian animal market.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES